Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hip fracture

Atypical Fractures Associated with Bisphosphonates

Michele B. Kaufman, PharmD, BCGP  |  November 1, 2014

Plus, FX006, odanacatib and other rheumatology drug news, safety updates

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone DisordersPain SyndromesSoft Tissue Pain Tagged with:bisphosphonatesdrugFibromyalgiaFracturesFX006KaufmanodanacatibOsteoporosisosteoporosis treatmentsrheumatologySafety

New Treatments Needed to Prevent Fractures in Osteoporosis

Ellen M. Field, MD, FACR, CCD  |  June 1, 2014

Current therapies target pathways of bone remodeling, but rheumatologists say a better understanding of the mechanisms of bone resorption, formation is needed to make an impact

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:Biologicsbone remodelingimagingOsteoporosispatient careRheumatoid arthritisrheumatologistUltrasound

Glucocorticoids a Fracture Risk at Any Dose

Kathy Holliman  |  March 18, 2011

Updated recommendations advocate doing more to determine fracture risk and the need for preventive therapy

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:boneFracturesGlucocorticoid-Induced OsteoporosisGlucocorticoidsGuidelinesOsteoporosispatient careSteroids

Concrete Relief for Vertebral Fractures

Kurt Ullman  |  April 1, 2008

PVA reduces fracture pain—but is it overused?

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:Joint SurgeryOsteoporosisPainTreatmentvertebral fracture

Alendronate May Provide Cardiovascular Benefits; Plus FDA Approves Subcutaneous Tocilizumab

Michele B. Kaufman, PharmD, BCGP  |  May 28, 2018

New research has linked alendronate to reduced cardiovascular death in hip fracture patients…

Filed under:Drug Updates Tagged with:alendronatecardiovascularFDAFractureship fractureJuvenile Arthritis (JIA)polyarticular juvenile idiopathic arthritistocilizumabU.S. Food and Drug Administration (FDA)

ACR Releases Update to Glucocorticoid-Induced Osteoporosis Guideline

Ruth Jessen Hickman, MD  |  October 10, 2023

The ACR recently released an update on the prevention and treatment of glucocorticoid-induced osteoporosis.1 The guideline, which includes information on the new therapies abaloparatide and romosozumab, emphasizes the importance of shared decision making by patients and clinicians, and also gives information on the importance of sequential therapy after stopping certain osteoporotic prevention therapies. Fracture Prevention…

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesGlucocorticoid-Induced Osteoporosis

Why Would You Ever Write a Letter of Recommendation or Support?

Marian T. Hannan, DSc, MPH  |  April 7, 2023

I vividly recollect asking my physics professor for a letter of recommendation. I sat in the front row of his lectures and visited his office hours most weeks in the semester. He turned me down because he was “too busy.” I was devastated—and panicked about asking my next choice for letter writer. On the plus…

Filed under:Career DevelopmentEducation & TrainingProfessional Topics Tagged with:Advocacyrecommendations

Highlights from the ACR Review Course 2022

Samantha C. Shapiro, MD  |  December 6, 2022

PHILADELPHIA—At ACR Convergence 2022, the much-anticipated ACR Review Course featured talks from eight experts. Topics reflected the heterogeneity of our field and included Sjögren’s disease, spondyloarthritis (SpA), osteoarthritis (OA), paraneoplastic rheumatic syndromes, metabolic bone disease, statin myopathy, Raynaud’s phenomenon and autoinflammatory syndrome. Here, I share highlights from this comprehensive, six-hour session. Sjögren’s Disease Sara S….

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone DisordersOther Rheumatic ConditionsSjögren’s Disease Tagged with:ACR Convergence 2022ACR Convergence 2022 – ASautoinflammatory diseasemetabolic bone diseaseosteoarthritis (OA)paraneoplastic rheumatic syndromesRaynaud’s phenomenonSjogren'sspondyloarthritis (SpA)statin myopathy

Challenging Cases in Osteoporosis: Tips from an Expert

Samantha C. Shapiro, MD  |  June 18, 2022

Using three complicated patient cases, Kenneth G. Saag, MD, MSc, shared his expertise on osteoporosis and walked through his thought process and the literature, during a session of the 2022 ACR Education Exchange.

Filed under:ConditionsEducation & TrainingMeeting ReportsOsteoarthritis and Bone DisordersOther ACR meetings Tagged with:ACR Education Exchangebisphosphonatesdenosumabeducation and trainingOsteoporosisromosozumab

Denosumab vs. Zoledronate: An Analysis of Treatments for Low Bone Mineral Density in Patients with HIV

Michele B. Kaufman, PharmD, BCGP  |  May 9, 2022

In a small study of men with low bone mineral density (BDM) living with HIV and taking anti-retroviral therapy, both zoledronate or denosumab were well tolerated and effective for bone mineral density of the lumbar spine and femoral neck.

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)denosumabHIVOsteoporosisosteoporosis treatmentszoledronate

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 27
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences